Bio-Cancer Treatment, founded in 2000, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative biologics for the treatment of human cancers and auto-immune disorders. The company's product candidate portfolio includes BCT-100 and BCT-200, both pegylated recombinant human arginase 1 (pegArg1) compounds that work to reduce tumor growth and ultimately cancer death. BCT-100 is currently undergoing a Phase I clinical trial in the US for treating arginine-auxotrophic solid tumors and a Phase II clinical trial in Hong Kong for the treatment of acute myeloid leukemia (AML). BCT-200, which features modifications to the BCT-100 amino acid sequence, is at the pre-IND stage.